psyence logo.png
The Psyence Group Announces its Formal Entry into Jamaica with the Incorporation of its Wholly Owned Subsidiary, Psyence Jamaica Limited
June 08, 2021 07:30 ET | Psyence Group Inc.
TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (“Psyence” or the “Company”) (PSYG:CSE), a Canadian public biotechnology company with a global presence, is pleased to announce the...
psyence logo.png
Psyence Group Corporate Update
May 27, 2021 07:30 ET | Psyence Group Inc.
TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and...
psyence logo.png
Psyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms and Development of Psilocybin Formulations
March 31, 2021 07:00 ET | Psyence Group Inc.
VANCOUVER, British Columbia, March 31, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence”), and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure...
psyence logo.png
Psyence Group Announces Partnership With Base Pair Health and Strengthens Management Team
March 05, 2021 07:30 ET | Psyence Group Inc.
TORONTO, March 05, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to announce that it has entered into a Service Level Agreement with Singapore-based...
psyence logo.png
Psyence Group Launches its Functional Mushroom Brand, “Goodmind”
March 04, 2021 07:30 ET | Psyence Group Inc.
TORONTO AND CAPE TOWN, South Africa, March 04, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc., a leading platform in naturally derived psychedelic therapy and the development and commercialization of...
psyence logo.png
Psyence Group Signs Collaboration Agreement with Leading Jamaican Psilocybin Retreat Provider to Conduct Observational Study
February 10, 2021 07:30 ET | Psyence Group Inc.
TORONTO and KINGSTON, Jamaica, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc., through its wholly-owned subsidiary Psyence Therapeutics Corp. (“Psyence”), is pleased to announce it has entered...
psyence logo.png
Psyence Group Presenting at Canaccord Genuity Conference "New Paradigms & Treatment Approaches in Mental Health"
February 03, 2021 17:15 ET | Psyence Group Inc.
TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to announce that its Co-founder and CEO, Jody Aufrichtig will be presenting at the...
psyence logo.png
Psyence Group Completes First Cultivation Cycle of Medical Psilocybin Mushrooms at Its Commercially Licensed Facility
January 29, 2021 07:30 ET | Psyence Group Inc.
TORONTO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (“Psyence” or the “Company”) is pleased to announce that it has concluded its first cultivation and harvest cycle of natural medical...
psyence logo.png
Psyence Group to Commence Trading (CSE:PSYG) on January 27, 2021
January 26, 2021 12:31 ET | Psyence Group Inc.
TORONTO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (“Psyence” or the “Company”), is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange...
psyence logo.png
Psyence Group Inc Completes Reverse Takeover Transaction and Completes Non-brokered Financing
January 20, 2021 16:24 ET | Psyence Group Inc.
TORONTO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence" or the "Company"), formerly Cardinal Capital Partners Inc., is pleased to announce the successful completion of the...